ESR1 and neoplasm: Pharmacological intervention (25 mg kg−1, literature‐based drug concentration) significantly attenuated tumor progression (Figure8A–C) through suppression of ARL3 and its downstream reduction of ERα and proliferation marker Ki67 expression level (Figure 8D), while combination therapy induced synergistic tumor regression when paired with endocrine agents.